NeuroSense Provides Business Update and Progress for the First Half of 2026

CAMBRIDGE, Mass., Sept. 25, 2026 // -- Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided a business update with corporate highlights…